INNOVIVA, INC. Expense Breakdown
No Expense Breakdown for INVA on this site yet.
- 2026-06-30: Products $22.35M.
- 2025-06-30: Products $10.59M.
Source checked: the stored Expense Breakdown page for INVA.
Expenses by product
Cost of sales: each quarter (3 month)
| Quarter end | Products |
|---|---|
| 2026-06-30 | $22.35M |
| 2025-06-30 | $10.59M |
Research and development: each quarter (3 month)
| Quarter end | Internal Expenses | External Services |
|---|---|---|
| 2026-06-30 | $2.73M | $2.46M |
| 2025-06-30 | $1.20M | $6.78M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |